Bafna Pharmaceuticals files Reg. 31(4) disclosure for substantial acquisition

M&A / JV 30 Jun 2026 · Filed / open· ✓ Verified

Under SEBI (SAST) Regulations 2011, Regulation 31(4) requires immediate disclosure of substantial acquisitions of shares and voting rights. Bafna Pharmaceuticals filed this disclosure at NSE on 30 June 2026. The filing itself is a regulatory gate: depending on the acquisition percentage, an open offer may be mandated under Regulation 4. Full transaction details (acquirer name, shares/percentage, consideration) must be verified from the full PDF filing or company investor-relations page.

Why it mattersA Regulation 31(4) disclosure is mandatory within 2 business days of crossing key shareholding thresholds (5%, 10%, 15%, etc.); the filing does not confirm completion, only that the threshold has been crossed-practitioners must track the formal open offer announcement (if applicable under Reg. 4) and any subsequent Rule 5 exemption orders.
SectorPharma & Healthcare
[object Object][object Object][object Object][object Object][object Object][object Object][object Object]

Sources

Open in the live tracker →

Related deals